Literature DB >> 26588001

Risk of bias in model-based economic evaluations: the ECOBIAS checklist.

Charles Christian Adarkwah1,2, Paul F van Gils3, Mickaël Hiligsmann1, Silvia M A A Evers1,4.   

Abstract

Several biases can occur when performing economic evaluations (EE) and it is important for researchers to minimize these biases, as they can significantly affect economic outcomes. This review aims, firstly, to identify biases that can occur in model-based EE and to illustrate their impact on economic outcomes and, secondly, to present a checklist for assessing the overall risk of bias in EE. Eleven biases that can occur in model-based studies were identified through a scoping review, scrutiny of systematic reviews, the authors' own experiences and discussions with experts. By combining these biases that can occur in model-based studies with biases that were identified for trial-based studies in a previous article, a 22-item checklist was developed for assessing bias in EE - the ECOBIAS checklist. This study and the ECOBIAS checklist aim to help researchers reduce biases in future EE, particularly in model-based EE. Nevertheless, further validation of the checklist is needed.

Keywords:  bias; checklist; cost and outcomes; economic evaluation; model-based studies; systematic error

Mesh:

Year:  2015        PMID: 26588001     DOI: 10.1586/14737167.2015.1103185

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  19 in total

1.  Cost effectiveness of breast cancer screening and prevention: a systematic review with a focus on risk-adapted strategies.

Authors:  Nikolai Mühlberger; Gaby Sroczynski; Artemisa Gogollari; Beate Jahn; Nora Pashayan; Ewout Steyerberg; Martin Widschwendter; Uwe Siebert
Journal:  Eur J Health Econ       Date:  2021-08-03

Review 2.  Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs.

Authors:  Salah Ghabri; Laurent Lam; François Bocquet; Hans-Martin Spath
Journal:  Pharmacoeconomics       Date:  2020-05       Impact factor: 4.981

3.  Cost Effectiveness of Human Papillomavirus Vaccination for Men Who have Sex with Men; Reviewing the Available Evidence.

Authors:  Didik Setiawan; Abrham Wondimu; KohJun Ong; Albert Jan van Hoek; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2018-08       Impact factor: 4.981

4.  Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies.

Authors:  Bhavani Shankara Bagepally; Akhil Sasidharan
Journal:  Eur J Clin Pharmacol       Date:  2021-10-27       Impact factor: 2.953

5.  The Cost-Effectiveness of Adjunctive Lifestyle Interventions for the Management of Cancer: A Systematic Review.

Authors:  Andrew Gallagher; Violetta Shersher; Duncan Mortimer; Helen Truby; Terry Haines
Journal:  Appl Health Econ Health Policy       Date:  2022-09-27       Impact factor: 3.686

Review 6.  Methodological Approaches to Cost-Effectiveness Analysis in Saudi Arabia: What Can We Learn? A Systematic Review.

Authors:  Fatma Maraiki; Shouki Bazarbashi; Paul Scuffham; Haitham Tuffaha
Journal:  MDM Policy Pract       Date:  2022-03-21

Review 7.  Incremental Net Monetary Benefit of Bariatric Surgery: Systematic Review and Meta-Analysis of Cost-Effectiveness Evidences.

Authors:  Prapaporn Noparatayaporn; Montarat Thavorncharoensap; Usa Chaikledkaew; Bhavani Shankara Bagepally; Ammarin Thakkinstian
Journal:  Obes Surg       Date:  2021-04-24       Impact factor: 4.129

8.  Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review.

Authors:  Thomas Grochtdreis; Hans-Helmut König; Alexander Dobruschkin; Gunhild von Amsberg; Judith Dams
Journal:  PLoS One       Date:  2018-12-05       Impact factor: 3.240

9.  Informing policy makers on the efficiency of population level tobacco control interventions in Asia: A systematic review of model-based economic evaluations.

Authors:  Ariuntuya Tuvdendorj; Yihui Du; Grigory Sidorenkov; Erik Buskens; Geertruida H de Bock; Talitha Feenstra
Journal:  J Glob Health       Date:  2020-12       Impact factor: 4.413

10.  Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies.

Authors:  Bhavani Shankara Bagepally; Usa Chaikledkaew; Yogesh Krishnarao Gurav; Thunyarat Anothaisintawee; Sitaporn Youngkong; Nathorn Chaiyakunapruk; Mark McEvoy; John Attia; Ammarin Thakkinstian
Journal:  BMJ Open Diabetes Res Care       Date:  2020-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.